Twist Bioscience is anticipating a significant boost in sales for the second quarter of the fiscal year 2024, with projected revenues ranging from $70 million to $71 million. This positive outlook marks a notable increase compared to the previous quarter, where the company generated approximately $60 million to $61 million in revenue. Additionally, Twist Bioscience expects to achieve a gross margin of 39% for the upcoming quarter, demonstrating a considerable improvement from the previous gross margin of around 30%.
Looking ahead to the entire fiscal year 2024, Twist Bioscience has raised its revenue guidance to a range of $288 million to $293 million. This upward adjustment represents a remarkable growth rate of 18% to 20% when compared to the consensus estimate of $289.69 million. Notably, the company predicts that its Next-Generation Sequencing (NGS) sales will contribute significantly to its overall performance, with an expected total of approximately $120 million for the year.
As for the immediate future, Twist Bioscience’s sales forecast for the next quarter stands at $67.59 million, with a projected range of $67.00 million to $68.36 million. These figures indicate a continued positive trajectory for the company’s financial performance.
Investors and stakeholders eagerly await Twist Bioscience’s earnings report, which is scheduled to be published on February 2nd, 2024. This report will provide a comprehensive overview of the company’s financial results and shed further light on its continued growth and success.
TWST Stock Soars on Impressive Performance and Positive Market Sentiment
On February 2, 2024, Twist Bioscience Corporation (TWST) experienced an impressive surge in its stock performance. As reported by CNN Money, TWST was trading near the top of its 52-week range and was positioned above its 200-day simple moving average. This positive momentum set the stage for an exciting day of trading for the biotechnology company. The day began with a notable price change for TWST shares. Since the market last closed, the price of TWST shares had increased by $0.86, representing a significant 2.65% rise. This surge in price indicated a strong demand for TWST stock and suggested that investors were optimistic about the company’s future prospects. The previous closing price for TWST shares stood at $33.26, and the stock had already shown signs of growth in pre-market trading. Prior to the market opening, TWST had already risen by an impressive $4.51. This pre-market surge further fueled investors’ excitement and heightened expectations for the day ahead. The strong performance of TWST on February 2, 2024, can be attributed to several factors. Firstly, the fact that the stock was trading near the top of its 52-week range indicated that investors had confidence in the company’s ability to deliver positive results. This confidence may have been bolstered by TWST’s consistent performance over the past year. Additionally, the stock’s position above its 200-day simple moving average further reinforced the positive sentiment surrounding TWST. This moving average is a commonly used technical indicator that reflects the average price of a stock over a specific period. When a stock is trading above its 200-day moving average, it suggests that the stock is in an upward trend and may continue to rise. The rise in TWST stock price during pre-market trading also hinted at the market’s positive response to the company’s recent developments or news. Investors may have been reacting to favorable announcements, such as promising clinical trial results or significant partnerships that could potentially drive future growth for TWST. As the market opened on February 2, 2024, all eyes were on TWST to see if the positive momentum would continue throughout the trading day. Investors were eagerly awaiting further news and developments that could potentially impact the stock’s performance. It is important to note that stock market performance can be volatile and subject to various factors, including market conditions, investor sentiment, and company-specific news. Therefore, investors should exercise caution and conduct thorough research before making any investment decisions. In conclusion, TWST’s stock performance on February 2, 2024, was off to an impressive start. Trading near the top of its 52-week range and above its 200-day simple moving average, TWST showcased its potential for growth. The rise in stock price since the market last closed, coupled with the significant pre-market surge, indicated a promising day ahead for the biotechnology company. As investors eagerly awaited further news and developments, TWST’s performance on this day demonstrated its ability to capture the attention and enthusiasm of market participants.
TWST Stock Performance: Mixed Day on February 2, 2024, Amidst Revenue Growth and Net Loss Improvement
TWST stock experienced a mixed day on February 2, 2024. Twist Bioscience Corporation generated a total revenue of $245.11 million in the past year, a 20.41% increase compared to the previous year. However, the last quarter’s revenue of $66.95 million showed no growth. The net income for the past year was -$204.62 million, a 6.08% improvement compared to the previous year. The net loss in the last quarter was -$46.24 million, showing no change from the previous quarter. The EPS for the past year was -$3.60, an 11.03% improvement compared to the previous year. The EPS in the last quarter was -$0.81, showing no change from the previous quarter. The lack of growth in the last quarter may have influenced TWST stock’s performance on February 2, 2024, as investors may have been cautious. It is important to consider various factors before making investment decisions.
